Clinical trial of blood-brain barrier disruption by pulsed ultrasound

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J. F., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,890

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

Calvert, H., Newell, D. R., Gumbrell, L. A., O’Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,862

Noninvasive MR Imaging–guided Focal Opening of the Blood-Brain Barrier in Rabbits

Hynynen, K., McDannold, N. J., Vykhodtseva, N. I., & Jolesz, F. A. (2001) · Radiology · doi:10.1148/radiol.2202001804 · Cited by 1,463

Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease

Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290

Accelerated Titration Designs for Phase I Clinical Trials in Oncology

Simon, R. M., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 641

Temporary Disruption of the Blood–Brain Barrier by Use of Ultrasound and Microbubbles: Safety and Efficacy Evaluation in Rhesus Macaques

McDannold, N. J., Arvanitis, C., Vykhodtseva, N. I., & Livingstone, M. S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0128 · Cited by 600

Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model

Leinenga, G., & Götz, J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2512 · Cited by 498

Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment.

Liu, H.-L., Hua, M., Chen, P.-Y., Chu, P.-C., Pan, C.-H., Yang, H.-W., Huang, C.-Y., Wang, J.-J., Yen, T., & Wei, K.-C. (2010) · Radiology · doi:10.1148/radiol.10090699 · Cited by 387

Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound

Jordão, J. F., Thévenot, E., Markham-Coultes, K., Scarcelli, T., Weng, Y.-Q., Xhima, K., O'Reilly, M., Huang, Y., McLaurin, J., Hynynen, K., et al. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.05.008 · Cited by 326

Improved Anti-Tumor Effect of Liposomal Doxorubicin After Targeted Blood-Brain Barrier Disruption by MRI-Guided Focused Ultrasound in Rat Glioma

Treat, L. H., McDannold, N. J., Zhang, Y., Vykhodtseva, N. I., & Hynynen, K. (2012) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2012.04.015 · Cited by 296

The blood–brain barrier and blood–tumour barrier in brain tumours and metastases

Arvanitis, C., Ferraro, G. B., & Jain, R. K. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0205-x · Cited by 1,919

Smart cancer nanomedicine

van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F. M., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,279

Strategies for delivering therapeutics across the blood–brain barrier

Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138

Rethinking cancer nanotheranostics

Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. S. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,113

Challenges to curing primary brain tumours

Aldape, K., Brindle, K. M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M. R., Gottardo, N., Gutmann, D. H., Hargrave, D., Holland, E. C., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0177-5 · Cited by 959

Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma

Idbaïh, A., Canney, M. S., Belin, L., Desseaux, C., Vignot, A., Bouchoux, G., Asquier, N., Law-Ye, B., Leclercq, D., Bissery, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3643 · Cited by 367

Temporary disruption of the blood-brain barrier using an implantable ultrasound system for recurrent glioblastoma patients under IV carboplatin chemotherapy: initial phase 1/2a clinical trial observations

Carpentier, A. C., Canney, M. S., Vignot, A., Horodyckid, C., Goldwirt, L., Leclercq, D., Delattre, J., Chapelon, J., & Idbaïh, A. (2015) · Journal of Therapeutic Ultrasound · doi:10.1186/2050-5736-3-s1-o14 · Cited by 11

A phase I/IIa study to evaluate the safety and efficacy of blood-brain barrier (BBB) opening with the SonoCloud-9 implantable ultrasound device in recurrent glioblastoma patients receiving IV carboplatin.

Idbaïh, A., Ducray, F., Stupp, R., Baize, N., Chinot, O. L., Groot, J. F. D., Guyotat, J., Sonabend, A. M., Meneï, P., Dufour, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.2049 · Cited by 11

News in brief

(2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30136-3

OS07.3.A Phase 1/2 clinical trial of blood-brain barrier opening with the SonoCloud-9 implantable ultrasound device in recurrent glioblastoma patients receiving IV carboplatin

Idbaïh, A., Sonabend, A. M., Stupp, R., Chinot, O. L., Dufour, H., Ducray, F., Meneï, P., de Groot, J., Desseaux, C., & Carpentier, A. C. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac174.048 · Cited by 2

ACTR-57. A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BLOOD-BRAIN BARRIER (BBB) OPENING WITH A NINE-EMITTER IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS PRIOR TO CARBOPLATIN

Idbaïh, A., Ducray, F., DeGroot, J. F., Stupp, R., Guyotat, J., Lesniak, M. S., Sonabend, A. M., Weinberg, J. S., Desseaux, C., Canney, M. S., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz175.099

Phase I/II study of an implantable device delivering low intensity pulsed ultrasound (LIPU) to disrupt the blood-brain barrier (BBB) followed by intravenous carboplatin chemotherapy in patients with recurrent glioblastoma (GBM).

Idbaïh, A., Canney, M. S., Vignot, A., Law-Ye, B., Dehais, C., Houillier, C., Laigle–Donadey, F., Delattre, J., & Carpentier, A. C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.2034 · Cited by 3

CTNI-20. RESULTS OF A PHASE 1/2 CLINICAL TRIAL OF BLOOD-BRAIN BARRIER (BBB) OPENING WITH THE SONOCLOUD-9 IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING IV CARBOPLATIN

Carpentier, A. C., Sonabend, A. M., Stupp, R., Chinot, O. L., Dufour, H., Ducray, F., Meneï, P., de Groot, J., Weinberg, J. S., Desseaux, C., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac209.286 · Cited by 2

Ultrasound-induced blood-brain barrier disruption for the treatment of gliomas and other primary CNS tumors

Beccaria, K., Canney, M. S., Bouchoux, G., Desseaux, C., Grill, J., Heimberger, A. B., & Carpentier, A. C. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.013 · Cited by 62

101 Focused Ultrasound–Induced Blood–Brain Barrier Disruption for Enhanced Drug Delivery in Glioblastoma: A Clinical Trial–Based Analysis

Karim, M. H. (2026) · Neurosurgery · doi:10.1227/neu.0000000000003964_101